48L0 Stock Chart & Stats
€3.28
--
Market closed
€3.28
--
Day’s Range― - ―
52-Week Range€3.02 - €3.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€5.40M
Enterprise Value€13.85M
Total Cash (Recent Filing)€11.64M
Total Debt (Recent Filing)€23.38M
Price to Earnings (P/E)―
Beta-0.55
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.40
Shares Outstanding14,410,621
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.94
Price to Sales (P/S)0.75
P/FCF Ratio-0.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.56
Revenue Forecast (FY)€11.15M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA >107% revenue inflection to $7.7M demonstrates meaningful commercial traction and validates product-market fit. Sustained top-line acceleration improves operating leverage potential, supports scale of recurring consumables revenue, and underpin longer-term pathway to unit economics improvement.
High Customer Retention & DistributionA ~90% renewal rate and a third major GPO relationship create durable demand channels and channel stickiness. Broad hospital access via GPOs and global clearances improves recurring consumables adoption and lowers incremental sales costs, supporting predictable annuity-like revenue over time.
Gen 2 Platform TAM ExpansionGen 2's transport capability and longer maintenance cycles materially enlarge addressable market and use cases. If approved, structural product differentiation would create new clinical settings, higher device utilization, and uplift recurring consumable demand across a much larger global TAM.
Bears Say
Limited LiquidityCash on hand is below outstanding long-term debt while burn remains ~$/yr scale, leaving a tight runway absent financing or major revenue inflows. Structural liquidity pressure can force dilutive financings or cutbacks, constraining sustained commercial investment and R&D over the medium term.
Persistent Net LossesLarge recurring operating and net losses indicate the business is not yet self-funding; negative returns on equity and ongoing cash outflows limit internal capital for scaling. Continued loss-making status raises execution and financing risk before durable profitability is achieved.
Regulatory/Timing DependenceMaterial portion of the multi-year growth plan and TAM expansion depends on FDA approval of Gen 2. Regulatory delay or unfavorable labeling would postpone or reduce revenue opportunities, amplifying financing needs and exposing growth targets to a single regulatory outcome risk.
Beyond Air News
48L0 FAQ
What was Beyond Air’s price range in the past 12 months?
Beyond Air lowest stock price was €3.02 and its highest was €3.28 in the past 12 months.
What is Beyond Air’s market cap?
Beyond Air’s market cap is €5.40M.
When is Beyond Air’s upcoming earnings report date?
Beyond Air’s upcoming earnings report date is Aug 11, 2026 which is in 30 days.
How were Beyond Air’s earnings last quarter?
Beyond Air released its earnings results on Jun 26, 2026. The company reported -€0.674 earnings per share for the quarter, missing the consensus estimate of -€0.497 by -€0.178.
Is Beyond Air overvalued?
According to Wall Street analysts Beyond Air’s price is currently Overvalued.
Does Beyond Air pay dividends?
Beyond Air does not currently pay dividends.
What is Beyond Air’s EPS estimate?
Beyond Air’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyond Air have?
Beyond Air has 14,410,621 shares outstanding.
What happened to Beyond Air’s price movement after its last earnings report?
Beyond Air reported an EPS of -€0.674 in its last earnings report, missing expectations of -€0.497. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Beyond Air?
Currently, no hedge funds are holding shares in DE:48L0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyond Air
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
48L0 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear commercial progress: strong revenue growth (>107% to $7.7M), improved gross profit and operating results, high customer retention (~90%), expanded GPO relationships and global clearances, and a compelling product roadmap with Gen 2 that could materially expand the addressable market. Offsetting these positives are remaining sizable net losses ($33.2M), limited cash on hand ($17.3M) versus $21.6M of long-term debt, increased other expenses, a Nasdaq compliance-driven reverse split, and dependence on uncertain FDA timing for Gen 2 approval (which underpins 2027 guidance). Overall, momentum and execution improvements are evident, but material execution and financing/regulatory risks remain.View all DE:48L0 earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---